Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 130,777 |
|
|||||
| News | - | ||||||
| Day High | 3.77 | Low High |
|||||
| Day Low | 3.51 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Mural Oncology PLC | MURA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.01 | 0.28% | 3.58 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.59 | 3.51 | 3.77 | 3.58 | 3.57 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,552 | 130,777 | $ 3.61 | $ 472,371 | - | 3.23 - 17.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:18:35 | 20 | $ 3.55 | USD |
Mural Oncology PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 60.59M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Mural Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MURA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.75 | 3.88 | 3.51 | 3.65 | 90,290 | -0.17 | -4.53% |
| 1 Month | 3.69 | 4.1831 | 3.51 | 3.78 | 92,555 | -0.11 | -2.98% |
| 3 Months | 5.40 | 5.623 | 3.44 | 4.35 | 183,212 | -1.82 | -33.70% |
| 6 Months | 3.65 | 6.2499 | 3.23 | 4.40 | 355,134 | -0.07 | -1.92% |
| 1 Year | 16.69 | 17.00 | 3.23 | 4.34 | 427,966 | -13.11 | -78.55% |
| 3 Years | 16.69 | 17.00 | 3.23 | 4.34 | 427,966 | -13.11 | -78.55% |
| 5 Years | 16.69 | 17.00 | 3.23 | 4.34 | 427,966 | -13.11 | -78.55% |
Mural Oncology Description
| Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab. |
